French healthtech startup Lucis has raised $8.5 million in a seed funding round led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures.
- Founded in 2025 by Maxime Berthelot, Baptiste Debever, and Max Guerois, Lucis offers a preventive healthcare service that translates blood test results into actionable insights.
- Members complete check-ups at certified medical laboratories across France, the UK, Ireland, and Portugal, with results covering over 180 biomarkers including cardiovascular, metabolic, hormonal, renal, liver, and inflammatory indicators.
- The platform integrates AI analysis with medical review to track changes over time and generate personalized action plans in areas such as nutrition, exercise, sleep, supplements, and mental health.
- Since its launch, Lucis has served 3,000 customers, conducted over 500,000 clinical tests, and established a network of more than 400 European laboratories.
- Users undergo two blood draws per year and receive dashboard-based monitoring, turning complex biomarker data into clear guidance to detect imbalances early, support long-term wellness, and improve overall performance.
Our mission is to empower individuals to take ownership of their health by giving them a clear view of key indicators before symptoms even appear, and providing practical guidance to improve their well-being, without replacing physicians," claims Maxime Berthelot, CEO and co-founder of Lucis.
Details of the deal
- Lucis will use the $8.5 million funding to accelerate expansion in France, the UK, Ireland, and Portugal, grow its network of partner laboratories and clinicians, and further develop its AI-powered preventive health platform.
